Literature DB >> 7864831

Immunoprecipitation of opioid receptor-Go-protein complexes using specific GTP-binding-protein antisera.

Z Georgoussi1, G Milligan, C Zioudrou.   

Abstract

Solubilization of opioid receptors from rat cortical membranes that retained high-affinity guanine nucleotide-sensitive agonist binding was achieved using 10 mM CHAPS. We report the nature of the interactions of mu and delta opioid receptors with the guanine nucleotide-binding protein G(o) by immunoprecipitation of CHAPS extracts with selective G(o)alpha-subunit protein antisera. Antiserum IM1 raised against amino acids 22-35 of G(o)alpha selectively co-immunoprecipitated G(o)alpha-mu and G(o)alpha-delta opioid receptor complexes detected in the immunoprecipitates by specific [3H][D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin and [3H][D-Ser2,Leu5,Thr6]enkephalin binding respectively. By contrast, antisera directed against the C-terminal decapeptide (OC2) and the N-terminal hexadecapeptide (ON1) of isoforms of G(o)alpha were unable to immunoprecipitate solubilized opioid receptor-G(o) complexes, although both were able to immunoprecipitate solubilized G(o)alpha and have been shown to reduce the affinity of [D-Ala2,D-Leu5]enkephalin for opioid receptors in rat cortical membranes [Georgoussi, Carr and Milligan (1993) Mol. Pharmacol. 44, 62-69]. These findings demonstrate that CHAPS-solubilized mu and delta opioid receptors from rat cortical membranes form stable complexes with one or more variants of G(o).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7864831      PMCID: PMC1136483          DOI: 10.1042/bj3060071

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

Review 1.  Molecular biology of opioid receptors.

Authors:  T Reisine; G I Bell
Journal:  Trends Neurosci       Date:  1993-12       Impact factor: 13.837

2.  Receptor and effector interactions of Gs. Functional studies with antibodies to the alpha s carboxyl-terminal decapeptide.

Authors:  W F Simonds; P K Goldsmith; C J Woodard; C G Unson; A M Spiegel
Journal:  FEBS Lett       Date:  1989-06-05       Impact factor: 4.124

3.  Carboxyl terminal domain of Gs alpha specifies coupling of receptors to stimulation of adenylyl cyclase.

Authors:  S B Masters; K A Sullivan; R T Miller; B Beiderman; N G Lopez; J Ramachandran; H R Bourne
Journal:  Science       Date:  1988-07-22       Impact factor: 47.728

4.  Antibodies directed against synthetic peptides distinguish between GTP-binding proteins in neutrophil and brain.

Authors:  P Goldsmith; P Gierschik; G Milligan; C G Unson; R Vinitsky; H L Malech; A M Spiegel
Journal:  J Biol Chem       Date:  1987-10-25       Impact factor: 5.157

5.  Solubilization of active opiate receptors.

Authors:  W F Simonds; G Koski; R A Streaty; L M Hjelmeland; W A Klee
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

6.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

7.  Expression of neurotransmitter receptors and myc protooncogenes in subclones of a human neuroblastoma cell line.

Authors:  W Sadée; V C Yu; M L Richards; P N Preis; M R Schwab; F M Brodsky; J L Biedler
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

8.  Opioid receptors in magnesium-digitonin-solubilized rat brain membranes are tightly coupled to a pertussis toxin-sensitive guanine nucleotide-binding protein.

Authors:  Y H Wong; C D Demoliou-Mason; E A Barnard
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

9.  Reconstitution of rat brain mu opioid receptors with purified guanine nucleotide-binding regulatory proteins, Gi and Go.

Authors:  H Ueda; H Harada; M Nozaki; T Katada; M Ui; M Satoh; H Takagi
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

10.  Solubilization of the vasopressin receptor from rat liver plasma membranes. Evidence for a receptor X GTP-binding protein complex.

Authors:  T J Fitzgerald; R J Uhing; J H Exton
Journal:  J Biol Chem       Date:  1986-12-25       Impact factor: 5.157

View more
  7 in total

1.  Evidence for involvement of 3'-untranslated region in determining angiotensin II receptor coupling specificity to G-protein.

Authors:  Thomas J Thekkumkara; Stuart L Linas
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

2.  Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants.

Authors:  A Wise; M A Watson-Koken; S Rees; M Lee; G Milligan
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

Review 3.  Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS.

Authors:  Javier Garzón; María Rodríguez-Muñoz; Elena de la Torre-Madrid; Pilar Sánchez-Blázquez
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

4.  Purification of A1 adenosine receptor-G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling.

Authors:  Z Gao; A S Robeva; J Linden
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

5.  Approaches to Assess Functional Selectivity in GPCRs: Evaluating G Protein Signaling in an Endogenous Environment.

Authors:  Laura M Bohn; Lei Zhou; Jo-Hao Ho
Journal:  Methods Mol Biol       Date:  2015

6.  A method for the prediction of GPCRs coupling specificity to G-proteins using refined profile Hidden Markov Models.

Authors:  Nikolaos G Sgourakis; Pantelis G Bagos; Panagiotis K Papasaikas; Stavros J Hamodrakas
Journal:  BMC Bioinformatics       Date:  2005-04-22       Impact factor: 3.169

7.  Activation of delta-opioid receptors inhibits neuronal-like calcium channels and distal steps of Ca(2+)-dependent secretion in human small-cell lung carcinoma cells.

Authors:  E Sher; P Cesare; A Codignola; F Clementi; P Tarroni; A Pollo; V Magnelli; E Carbone
Journal:  J Neurosci       Date:  1996-06-01       Impact factor: 6.167

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.